论文部分内容阅读
尿激酶原(prourokinase,pro-UK)亦称单链尿激酶,是一种由411个氨基酸残基组成、分子量为54kDa的糖蛋白,经纤溶酶(p1asmin)作用变成尿激酶(又称双链尿激酶);它与尿激酶不同,能特异性作用于血栓,激活溶血系统,临床应用时不易引起全身性出血,是一种很有希望的新型溶血栓制剂,但自然界中含量甚微,难于大量制备。于是,人们希望通过基因工程手段来获得大量的尿激酶原。1989年,本实验室方继明等人在国内首次获得了pro-UK全长cDNA克隆,随后在中国仓鼠卵巢细胞(CHO)表达了有生物活性的尿激酶原,表达量为每24h 50～60IU/10~6细胞,但这一表达
Prourokinase (pro-UK), also known as single-chain urokinase, is a glycoprotein composed of 411 amino acid residues with a molecular weight of 54 kDa. It is converted to urokinase by p1asmin Double-stranded urokinase); it is different from urokinase, can act specifically on thrombus, activate the hemolysis system, clinical application is not easy to cause systemic bleeding, is a promising new thrombolytic agents, but the content is very small in nature , Difficult to prepare in large quantities. Thus, one hopes to obtain a large amount of pro-urokinase through genetic engineering. In 1989, Fang Jiming et al. Obtained the full-length pro-UK cDNA clone for the first time in China and subsequently expressed the biologically active prourokinase in Chinese hamster ovary cells (CHO) for 50-60 IU / 10 ~ 6 cells, but this expression